Couchbase, Inc.
US ˙ NasdaqGS ˙ US22207T1016

Introduction

This page provides a comprehensive analysis of the known insider trading history of Nbvm Gp, Llc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Nbvm Gp, Llc has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:LYRA / Lyra Therapeutics, Inc. 10% Owner 2,521,745
US:BASE / Couchbase, Inc. 10% Owner 0
US:MKFG / Markforged Holding Corporation 10% Owner 29,126,742
US:US57767EAB83 / Mavenir Systems, Inc., Term Loan 10% Owner 0
US:DWRE / Demandware Inc. 10% Owner 473,902
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Nbvm Gp, Llc. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases BASE / Couchbase, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BASE / Couchbase, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2021-07-26 BASE NBVM GP, LLC 94,791 24.0000 94,791 24.0000 2,274,984 44 51.58 2,614,336 114.92
2021-07-26 BASE NBVM GP, LLC 40,625 24.0000 40,625 24.0000 975,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BASE / Couchbase, Inc. Insider Trades
Insider Sales BASE / Couchbase, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BASE / Couchbase, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BASE / Couchbase, Inc. Insider Trades
Insider Purchases LYRA / Lyra Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BASE / Couchbase, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2023-05-31 LYRA NBVM GP, LLC 403,858 2.4300 8,077 121.5000 981,375 301 6.5300 -928,631 -94.63
2023-05-31 LYRA NBVM GP, LLC 197,946 2.4300 3,959 121.5000 481,009
2023-05-31 LYRA NBVM GP, LLC 1,203,612 2.4300 24,072 121.5000 2,924,777
2022-04-12 LYRA NBVM GP, LLC 1,076,851 4.2200 21,537 211.0000 4,544,311
2022-04-12 LYRA NBVM GP, LLC 527,806 4.2200 10,556 211.0000 2,227,341
2022-04-12 LYRA NBVM GP, LLC 765,010 4.2200 15,300 211.0000 3,228,342
2020-05-05 LYRA NBVM GP, LLC 117,439 16.0000 2,349 800.0000 1,879,024
2020-05-05 LYRA NBVM GP, LLC 57,561 16.0000 1,151 800.0000 920,976
2020-05-05 LYRA NBVM GP, LLC 75,000 16.0000 1,500 800.0000 1,200,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LYRA / Lyra Therapeutics, Inc. Insider Trades
Insider Sales LYRA / Lyra Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BASE / Couchbase, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2020-05-05 LYRA NBVM GP, LLC 11,360 16.0000 227 800.0000 181,760 365 8.44 -179,844 -98.95
2020-05-05 LYRA NBVM GP, LLC 5,568 16.0000 111 800.0000 89,088
2020-05-05 LYRA NBVM GP, LLC 7,255 16.0000 145 800.0000 116,080

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LYRA / Lyra Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Nbvm Gp, Llc as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2023-06-02 2023-05-31 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		P - Purchase 1,203,612 2,521,745 91.31 2.43 2,924,777 6,127,840
2023-06-02 2023-05-31 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		P - Purchase 197,946 1,107,370 21.77 2.43 481,009 2,690,909
2023-06-02 2023-05-31 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		P - Purchase 403,858 2,259,301 21.77 2.43 981,375 5,490,101
2022-04-14 2022-04-12 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		P - Purchase 765,010 1,318,133 138.31 4.22 3,228,342 5,562,521
2022-04-14 2022-04-12 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		P - Purchase 527,806 909,424 138.31 4.22 2,227,341 3,837,769
2022-04-14 2022-04-12 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		P - Purchase 1,076,851 1,855,443 138.31 4.22 4,544,311 7,829,969
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series G Preferred Stock 		C - Conversion -204,809 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series G Preferred Stock 		C - Conversion -477,888 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series F Preferred Stock 		C - Conversion -56,502 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series F Preferred Stock 		C - Conversion -131,840 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series E Preferred Stock 		C - Conversion -40,285 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series E Preferred Stock 		C - Conversion -93,999 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series D Preferred Stock 		C - Conversion -86,156 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series D Preferred Stock 		C - Conversion -201,031 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series C Preferred Stock 		C - Conversion -317,901 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series C Preferred Stock 		C - Conversion -317,901 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series B Preferred Stock 		C - Conversion -498,927 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series B Preferred Stock 		C - Conversion -498,927 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series A Preferred Stock 		C - Conversion -643,708 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Series A Preferred Stock 		C - Conversion -643,708 0 -100.00
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Common Stock 		P - Purchase 40,625 1,987,084 2.09 24.00 975,000 47,690,016
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Common Stock 		P - Purchase 94,791 2,689,172 3.65 24.00 2,274,984 64,540,128
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Common Stock 		C - Conversion 1,864,081 1,946,459 2,262.84
2021-07-26 2021-07-26 4 BASE Couchbase, Inc.
Common Stock 		C - Conversion 2,402,147 2,594,381 1,249.60
2021-07-21 3 BASE Couchbase, Inc.
Common Stock 		192,234
2021-07-21 3 BASE Couchbase, Inc.
Common Stock 		82,378
2021-07-14 3 MKFG Markforged Holding Corp
Common Stock 		29,126,742
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Warrants 		X - Other -13,449 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Warrants 		X - Other -10,322 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Warrants 		X - Other -21,060 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock 		C - Conversion -1,545,953 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock 		C - Conversion -1,186,496 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock 		C - Conversion -2,420,729 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock 		C - Conversion -1,995,489 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock 		C - Conversion -1,531,507 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock 		C - Conversion -3,124,633 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-4 Convertible Preferred Stock 		C - Conversion -2,391,895 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-4 Convertible Preferred Stock 		C - Conversion -1,835,743 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-4 Convertible Preferred Stock 		C - Conversion -3,745,346 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-3 Convertible Preferred Stock 		C - Conversion -2,929,790 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-3 Convertible Preferred Stock 		C - Conversion -2,248,569 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-3 Convertible Preferred Stock 		C - Conversion -4,587,608 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-2 Convertible Preferred Stock 		C - Conversion -2,088,772 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-2 Convertible Preferred Stock 		C - Conversion -1,603,102 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-2 Convertible Preferred Stock 		C - Conversion -3,270,702 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/C Convertible Preferred Stock 		C - Conversion -1,948,948 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/C Convertible Preferred Stock 		C - Conversion -1,495,786 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/C Convertible Preferred Stock 		C - Conversion -3,051,758 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/B Convertible Preferred Stock 		C - Conversion -1,647,727 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/B Convertible Preferred Stock 		C - Conversion -541,973 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/B Convertible Preferred Stock 		C - Conversion -1,105,754 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/A Convertible Preferred Stock 		C - Conversion -1,725,090 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/A Convertible Preferred Stock 		C - Conversion -567,420 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/A Convertible Preferred Stock 		C - Conversion -1,157,670 0 -100.00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		P - Purchase 75,000 553,123 15.69 16.00 1,200,000 8,849,968
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		P - Purchase 57,561 381,618 17.76 16.00 920,976 6,105,888
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		P - Purchase 117,439 778,592 17.76 16.00 1,879,024 12,457,472
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		S - Sale -7,255 478,123 -1.49 16.00 -116,080 7,649,968
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		X - Other 13,449 485,378 2.85 8.63 116,065 4,188,812
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		S - Sale -5,568 324,057 -1.69 16.00 -89,088 5,184,912
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		X - Other 10,322 329,625 3.23 8.63 89,079 2,844,664
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		S - Sale -11,360 661,153 -1.69 16.00 -181,760 10,578,448
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		X - Other 21,060 672,513 3.23 8.63 181,748 5,803,787
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		C - Conversion 471,929 471,929
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		C - Conversion 319,303 319,303
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock 		C - Conversion 651,453 651,453
2015-05-01 2015-04-29 4 MVNR MAVENIR SYSTEMS INC
Common Stock 		U - Other -1,826,275 0 -100.00 17.55 -32,051,126
2015-05-01 2015-04-29 4 MVNR MAVENIR SYSTEMS INC
Common Stock 		U - Other -831,072 0 -100.00 17.55 -14,585,314
2015-05-01 2015-04-29 4 MVNR MAVENIR SYSTEMS INC
Common Stock 		U - Other -1,695,587 0 -100.00 17.55 -29,757,552
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series E Convertible Preferred Stock 		C - Conversion -810,970 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series E Convertible Preferred Stock 		C - Conversion -622,407 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series E Convertible Preferred Stock 		C - Conversion -1,269,855 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series D Convertible Preferred Stock 		C - Conversion -1,604,421 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series D Convertible Preferred Stock 		C - Conversion -1,231,369 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series D Convertible Preferred Stock 		C - Conversion -2,512,281 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series C Convertible Preferred Stock 		C - Conversion -1,261,642 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series C Convertible Preferred Stock 		C - Conversion -968,291 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series C Convertible Preferred Stock 		C - Conversion -1,975,540 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series B Convertible Preferred Stock 		C - Conversion -3,539,575 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series B Convertible Preferred Stock 		C - Conversion -1,164,243 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series B Convertible Preferred Stock 		C - Conversion -2,375,330 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series A Convertible Preferred Stock 		C - Conversion -5,567,338 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series A Convertible Preferred Stock 		C - Conversion -1,831,222 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Series A Convertible Preferred Stock 		C - Conversion -3,736,119 0 -100.00
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Common Stock 		C - Conversion 1,826,276 1,826,276
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Common Stock 		C - Conversion 831,074 831,074
2013-11-15 2013-11-13 4 MVNR MAVENIR SYSTEMS INC
Common Stock 		C - Conversion 1,695,587 1,695,587
2013-08-19 2013-08-15 4 DWRE Demandware Inc
Common Stock 		S - Sale -131 473,902 -0.03 45.55 -5,967 21,586,236
2013-07-18 2013-07-16 4 DWRE Demandware Inc
Common Stock 		J - Other 4,510 9,372 92.76
2013-07-18 2013-07-16 4 DWRE Demandware Inc
Common Stock 		J - Other 4,510 9,372 92.76
2013-07-18 2013-07-16 4 DWRE Demandware Inc
Common Stock 		J - Other 12,597 26,172 92.80
2013-07-18 2013-07-16 4 DWRE Demandware Inc
Common Stock 		J - Other 73,270 73,270
2013-07-18 2013-07-16 4 DWRE Demandware Inc
Common Stock 		J - Other 93,682 194,636 92.80
2013-07-18 2013-07-16 4 DWRE Demandware Inc
Common Stock 		J - Other -473,771 474,033 -49.99
2013-07-18 2013-07-16 4 DWRE Demandware Inc
Common Stock 		J - Other -968,673 965,071 -50.09
2013-05-20 2013-05-16 4 DWRE Demandware Inc
Common Stock 		J - Other 2,343 4,862 93.01
2013-05-20 2013-05-16 4 DWRE Demandware Inc
Common Stock 		J - Other 2,343 4,862 93.01
2013-05-20 2013-05-16 4 DWRE Demandware Inc
Common Stock 		J - Other 6,543 13,575 93.05
2013-05-20 2013-05-16 4 DWRE Demandware Inc
Common Stock 		J - Other 38,054 78,954 93.04
2013-05-20 2013-05-16 4 DWRE Demandware Inc
Common Stock 		J - Other 48,658 100,954 93.04
2013-05-20 2013-05-16 4 DWRE Demandware Inc
Common Stock 		J - Other -473,902 947,804 -33.33
2013-05-20 2013-05-16 4 DWRE Demandware Inc
Common Stock 		J - Other -966,871 1,933,744 -33.33
2013-02-01 2013-01-31 4 DWRE Demandware Inc
Common Stock 		J - Other -473,902 1,421,706 -25.00
2013-02-01 2013-01-31 4 DWRE Demandware Inc
Common Stock 		J - Other -966,871 2,900,615 -25.00
2012-09-20 2012-09-18 4 DWRE Demandware Inc
Common Stock 		J - Other -473,902 1,895,608 -20.00
2012-09-20 2012-09-18 4 DWRE Demandware Inc
Common Stock 		J - Other -966,871 3,867,486 -20.00
2012-03-20 2012-03-20 4 DWRE Demandware Inc
Series D Convertible Preferred Stock 		C - Conversion -2,331,029 0 -100.00
2012-03-20 2012-03-20 4 DWRE Demandware Inc
Series D Convertible Preferred Stock 		C - Conversion -4,755,847 0 -100.00
2012-03-20 2012-03-20 4 DWRE Demandware Inc
Series C Convertible Preferred Stock 		C - Conversion -2,202,568 0 -100.00
2012-03-20 2012-03-20 4 DWRE Demandware Inc
Series C Convertible Preferred Stock 		C - Conversion -4,493,755 0 -100.00
2012-03-20 2012-03-20 4 DWRE Demandware Inc
Series B Convertible Preferred Stock 		C - Conversion -1,283,916 0 -100.00
2012-03-20 2012-03-20 4 DWRE Demandware Inc
Series B Convertible Preferred Stock 		C - Conversion -2,619,490 0 -100.00
2012-03-20 2012-03-20 4 DWRE Demandware Inc
Series A Convertible Preferred Stock 		C - Conversion -1,291,019 0 -100.00
2012-03-20 2012-03-20 4 DWRE Demandware Inc
Series A Convertible Preferred Stock 		C - Conversion -2,633,981 0 -100.00
2012-03-20 2012-03-20 4 DWRE Demandware Inc
Common Stock 		C - Conversion 2,369,510 2,369,510
2012-03-20 2012-03-20 4 DWRE Demandware Inc
Common Stock 		C - Conversion 4,834,357 4,834,357
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)